Clinical Trials

VROBIO announces new patients dosed in Gaucher disease and cystinosis trials

AVROBIO announced that the first patient has been dosed in the company’s GuardOne clinical trial, a Phase 1/2 investigational study evaluating AVR-RD-02 for Gaucher disease type 1.

Sunovion’s SEP-4199 fails to meet primary endpoint in SEP380-201 trial

Sunovion Pharmaceuticals said that a phase 2 study evaluating SEP-4199 as the treatment of major depressive episodes associated with bipolar I disorder (bipolar I depression) failed to meet its primary endpoint.

Sinovac Covid-19 vaccine collaboration with Butantan receives approval from Brazilian regulator for phase III trial

Sinovac Biotech ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced an update to its previously announced partnership with Butantan, a leading Brazilian producer of immunobiologic products and vaccines.

Regeneron begins Phase 3 trial of Covid-19 ‘antibody cocktail’ drug

Regeneron Pharmaceuticals has announced the commencement of Phase 3 trial with its investigational double-antibody cocktail REGN-COV2 to treat and prevent Covid-19 disease.

Idorsia announces positive results in second phase 3 study of daridorexant

Idorsia announced positive top-line results of the second pivotal Phase 3 study investigating 10 and 25 mg doses of its dual orexin receptor antagonist, daridorexant, in 924 adult and elderly patients (39.3% ≥ 65 years) with insomnia.

EUSA Pharma gets FDA nod for phase 3 Covid-19 trial for Siltuximab

EUSA Pharma said that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase 3 clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).

Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer

Daiichi Sankyo Company announced the first patient with triple negative breast cancer (TNBC) has been dosed in the ongoing phase 1 study assessing DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC).

Pfizer, BioNTech announce early positive data from SARS-CoV-2 trial

Pfizer and BioNTech announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine programme , Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic.

Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer

Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with atezolizumab (TECENTRIQ) in patients with metastatic castration-resistant prostate cancer (CRPC) who have been previously treated with one novel hormonal therapy.